Phase 1 Clinical Trial of A Novel CDK Inhibitor Dinaciclib (SCH 727965) in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 14 May 2018
At a glance
- Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Dexamethasone (Primary) ; Dinaciclib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 10 May 2018 Status changed from active, no longer recruiting to completed.
- 26 Jan 2017 Status changed from suspended to active, no longer recruiting.